| Page 28 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome

ABSTRACT

PURPOSE
Patients with myelodysplastic syndrome (MDS) are at risk of relapse after allogeneic hematopoietic cell transplantation. The utility of ultra-deep genomic testing to predict and the impact of conditioning intensity to prevent MDS relapse are unknown.

Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: a prospective study of feasibility, safety, and healthcare resource use

Abstract
Background
We evaluated feasibility, safety, and total resource use of subcutaneous immunoglobulin (SCIG) in a pilot study of patients who underwent allogeneic hematopoietic cell transplant (HCT) over a 6-month period.

Trading One Disease for Another: Patients With Chronic Graft-vs-Host Disease May Face Lifelong Complications

The field of allogeneic stem cell transplantation continues to improve survival for patients with previously incurable blood cancers. However, up to 50% of patients who undergo transplantation with donor cells will develop chronic graft-vs-host disease, a potentially deadly condition that can also cause lifelong complications.

Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?

Author(s): 
Abel GA, Kim HT, Hantel A, Steensma DP, Stone R, Habib A, Ho VT, Wadleigh M, El-Jawahri A, Alyea EP, DeAngelo DJ, Koreth J, Antin JH, Soiffer RJ, Cutler C
Primary Author: 
Abel GA
Journal Title: 
Leukemia
Original Publication Date: 
Jan 2021
Bone Marrow Disease(s): 

Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes

Author(s): 
Garcia-Manero G, Diez-Campelo M, Vellenga E, Jacoby MA, Merchan B, Breems D, Cortelezzi A, Doronin V, Gomez V, Beckers M, Della Porta MG, Varsos H, Xiu L, DeAngelis N, Nnane I, Rose E, van Eygen K
Primary Author: 
Garcia-Manero G
Journal Title: 
American Journal of Hematology
Original Publication Date: 
Jan 2021
Bone Marrow Disease(s): 

Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options

Author(s): 
Russell Lewis, Jan Philipp Bewersdorf, Amer M Zeidan
Primary Author: 
Lewis R
Journal Title: 
Cancer Management and Research
Original Publication Date: 
Jan 2021

For the majority of patients with lower-risk myelodysplastic syndrome (LR-MDS), one of the primary clinical goals is to alleviate the symptoms associated with the resultant cytopenias and to minimize the transfusion burden. While supportive

Bone Marrow Disease(s):